Brief: Vtv Therapeutics Announces FDA Orphan Drug Designation For Hppd In Sickle Cell Disease
07/10/2026 21:14
BRIEF-Vtv Therapeutics Announces FDA Orphan Drug Designation For Hppd In Sickle Cell Disease Oct 7 (Reuters) - vTv Therapeutics Inc VTVT.O:
VTV THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR HPPD IN SICKLE CELL DISEASE
VTV THERAPEUTICS - HPPD UNDER INVESTIGATION AS TREATMENT FOR SICKLE CELL DISEASE
Source text: ID:nGNX8cLgkh
Further company coverage: VTVT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on vTv Therapeutics
See all newsBrief: Vtv Therapeutics Announces FDA Orphan Drug Designation For Hppd In Sickle Cell Disease
vTv Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
vTv Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
vTv Therapeutics Q2 net loss widens on higher trial costs
Brief: VTv Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)